allopurinol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   61 Trials   61 Trials   3860 News 


«12345678910111213...5758»
  • ||||||||||  colchicine / Generic mfg., febuxostat / Generic mfg., allopurinol / Generic mfg.
    A MACHINE LEARNING-BASED PREDICTION MODEL FOR GOUT IN HYPERURICEMICS  (A2) -  May 11, 2024 - Abstract #EULAR2024EULAR_2759;    
    The findings suggest that a our had relatively good performance and high NPV for identifying hyperuricemic participants at risk of developing gout. High NPV means a good prediction of which hyperuricemic will not develop gout and might imply on clinical decisions regarding gout prevention therapy.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Metabolic and neurobehavioral disturbances induced by purine recycling deficiency in Drosophila. (Pubmed Central) -  May 3, 2024   
    Intriguingly, pan-neuronal expression of an LND-associated mutant form of human HGPRT (I42T), but not the wild-type enzyme, resulted in early locomotor defects and seizure in flies, similar to Aprt deficiency. Overall, our results suggest that Drosophila could be used in different ways to better understand LND and seek a cure for this dramatic disease.
  • ||||||||||  probenecid / Generic mfg., allopurinol / Generic mfg.
    Preclinical, Journal:  Effect and mechanism of Yiqing decoction on hyperuricemia rats. (Pubmed Central) -  Apr 28, 2024   
    These effects may be mediated through signaling pathways such as IL-17, HIF-1, and AGE-RAGE. Yiqing Fang offers potential as a treatment for hyperuricemia due to its multiple active components, targeting of various sites, and engagement of multiple pathways.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Stevens-Johnson syndrome and toxic epidermal necrolysis in Hong Kong. (Pubmed Central) -  Apr 24, 2024   
    This study showed that SJS/TEN are uncommon in Hong Kong but can cause substantial morbidity and mortality. Early recognition, prompt withdrawal of offending agents, and multidisciplinary supportive management are essential for improving clinical outcomes.
  • ||||||||||  colchicine / Generic mfg., allopurinol / Generic mfg.
    Preclinical, Review, Journal:  Herbal remedies in the management of hyperuricemia and gout: A review of in vitro, in vivo and clinical evidences. (Pubmed Central) -  Apr 24, 2024   
    Patients were found to use a panoply of natural remedies, mainly plants to treat hyperuricemia and gout, which have been validated to some extent by in vitro, in vivo, and clinical studies. Nonetheless, further research is needed to better understand the ethnopharmacological relationship of such herbal remedies.
  • ||||||||||  colchicine / Generic mfg., allopurinol / Generic mfg.
    Journal:  Gout and its management. (Pubmed Central) -  Apr 24, 2024   
    It is experienced as extremely painful episodes of joint inflammation that impact all aspects of the person's life. This Clinical Perspectives article provides an update on gout diagnosis, medications and strategies to improve the quality of gout care.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Xanthine oxidase inhibitory constituents from the roots of Ampelopsis japonica. (Pubmed Central) -  Apr 18, 2024   
    Molecular docking uncovered a unique interaction mode of 16 with the active site of XOD. The current study showed that the triterpenoids and polyphenols from A. japonica could serve as new lead compounds with the potential to speed up the development of novel XOD inhibitors with clinical potential to treat hyperuricaemia and gout.
  • ||||||||||  Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Trial completion date, Trial primary completion date:  A041501: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Apr 18, 2024   
    P3,  N=310, Suspended, 
    The current study showed that the triterpenoids and polyphenols from A. japonica could serve as new lead compounds with the potential to speed up the development of novel XOD inhibitors with clinical potential to treat hyperuricaemia and gout. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Retrospective data, Review:  Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis. (Pubmed Central) -  Apr 11, 2024   
    This highlights the need to sub classify the effect of UA-lowering therapies according to the pathological scenario, in order to identify those CKD patients that may benefit most from them. Systematic Review Registration: CRD42022306646 https://www.crd.york.ac.uk/prospero/.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Health literacy and gout characteristics in a primary care cohort. (Pubmed Central) -  Apr 8, 2024   
    Multiple logistic regression was used to obtain adjusted odds ratios (ORs) for the cross-sectional associations between health literacy and individual gout characteristics (frequency of flares, age at gout onset, history of oligo-/polyarticular flares, allopurinol use, allopurinol dose and serum urate level) with 95% CIs and adjustment for age, sex, deprivation and further education...Frequent flares and a history of oligo-/polyarticular flares were associated with poor health literacy. Since health literacy is an important determinant of health outcomes, it is important to consider health literacy when providing information and education to people with gout.
  • ||||||||||  prednisone / Generic mfg., colchicine / Generic mfg., allopurinol / Generic mfg.
    Journal:  Syracuse Hemoglobinopathy Presenting With Tophaceous Gout: A Case Report. (Pubmed Central) -  Apr 3, 2024   
    Most patients with hyperuricemia never go on to develop gout. However, having a condition that increases serum levels of uric acid should raise an astute clinician's suspicion when a patient presents with a history of hemoglobinopathy and joint pain.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    RESPONSE TO ALLOPURINOL AND FEBUXOSTAT ACCORDING TO THE FRACTIONAL EXCRETION OF URIC ACID (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1893;    
    Combined therapy was well-tolerated by most patients. Unlike febuxostat, which is a non-purine XOI inhibitor, allopurinol, a purine analogue, is more effective in patients with a low FEUA, probably due to reduced renal excretion of oxypurinol.
  • ||||||||||  colchicine / Generic mfg.
    CARDIOVASCULAR SAFETY OF COLCHICINE AND NSAID PROPHYLAXIS WITH URATE-LOWERING THERAPY INITIATION: TARGET TRIAL EMULATION (TTE) ANALYSES (Poster Tour 5) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_702;    
    In these target trial analyses emulating pragmatic trials of gout patients starting allopurinol in the general population, colchicine prophylaxis was associated with a lower risk of MI and MACE than NSAID, whereas the risk was unaltered compared with no prophylaxis. These TTE results agree with the known and expected cardiovascular effects of colchicine and NSAID, supporting colchicine as the preferred flare prophylaxis, particularly among gout patients with CV disease or risk factors.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Review, Journal:  Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases. (Pubmed Central) -  Mar 26, 2024   
    In terms of cardiovascular safety, clinical trials have indicated that xanthine oxidase inhibitors such as febuxostat are non-inferior to allopurinol and do not increase the risk of death or serious adverse events. Overall, these findings highlight the importance of managing hyperuricemia and utilizing urate-lowering therapy to mitigate the adverse cardiovascular effects associated with elevated uric acid levels.
  • ||||||||||  Krystexxa (pegloticase) / Amgen, Rituxan (rituximab) / Roche
    Resolution of Severe Tophi with Recombinant Uricase in A Kidney Transplant Recipient () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_955;    
    Recombinant uricase shows effectiveness in KTR with severe gout with significant tophi. Further clinical trials are warranted to evaluate the efficacy and safety of recombinant uricase in this high-risk population.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal:  Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review. (Pubmed Central) -  Mar 22, 2024   
    This case highlights importance of recognizing STLS with hypercalcemia and expediting work up for prompt treatment to preserve renal function. These factors encompassed age, gender, preexisting medical conditions (such as diabetes, hypertension, and chronic kidney disease), and the medications that patients were taking at the beginning of the study, which included non-steroidal anti-inflammatory drugs,
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Retrospective data, Review, Journal:  Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A (Pubmed Central) -  Mar 19, 2024   
    In the Chinese subgroup, febuxostat could increase the risk of ADHF (HR: 1.22, 95% CI: 1.01-1.48, p?<?0.05), CV death (HR: 1.25, 95% CI: 1.03-1.50, p?<?0.05), and all-cause mortality (HR: 1.07, 95% CI: 1.01-1.14, p?<?0.05) compared to allopurinol. In conclusion, the use of febuxostat, compared with allopurinol among Asian patients, was associated with a significantly increased risk of adverse CV events.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Allopurinol Disrupts Purine Metabolism to Increase Damage in Experimental Colitis. (Pubmed Central) -  Mar 17, 2024   
    Of particular significance, the in vivo investigation identified that a therapeutically relevant allopurinol dose shifts adenylate and creatine metabolism, leading to AMPK dysregulation and disrupted proliferation to attenuate wound healing and increased tissue damage in murine experimental colitis. Collectively, these findings underscore the importance of purine salvage on cellular metabolism and gut health in the context of IBD and provide insight regarding the use of allopurinol in patients with IBD.
  • ||||||||||  allopurinol / Generic mfg.
    RAD50 BLOCKS THE PROTECTIVE EFFECTS OF URIC ACID-LOWERING THERAPY AGAINST NAFLD IN FEMALES (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_3824;    
    Hyperuricemia remission significantly reduces the risk of incident NAFLD and enhances NAFLD remission in males. However, RAD50 blocks the protective effects of uric acid-lowering therapy against NAFLD in females.
  • ||||||||||  colchicine / Generic mfg., allopurinol / Generic mfg.
    Journal, Adverse events:  How common are side effects of treatment to prevent gout flares when starting allopurinol? (Pubmed Central) -  Mar 13, 2024   
    Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. Ann Rheum Dis 2023;82:1618-25.To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/how-common-are-side-effects-of-treatment-to-prevent-gout-flares-when-starting-allopurinol/.
  • ||||||||||  Enrollment open, Phase classification, Trial completion date, Trial primary completion date:  TRUST: Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout (clinicaltrials.gov) -  Mar 12, 2024   
    P4,  N=650, Recruiting, 
    Ann Rheum Dis 2023;82:1618-25.To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/how-common-are-side-effects-of-treatment-to-prevent-gout-flares-when-starting-allopurinol/. Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Nov 2026 --> Nov 2028